药物研发管线：全流程各阶段完整指南

ByAdrien Laurent, CEO at IntuitionLabs• 10/10/2025 • 90 min read Executive Summary Drug development is a long, complex, and high-stakes process by which new therapeutic drugs are discovered, tested,and brought to market. This report provides an in-depth examination of the end-to-end drug development pipeline,highlighting each stage from initial drug discovery through clinical trials, regulatory approval, and post-marketsurveillance. Key findings are summarized as follows: Scope and Scale:Developing a new drug typically takes over a decade (often 10–15 years) and can cost on the order of $1–2.2billionor more per successful drug [https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/] (Deloitte’s 2024 analysis of top-20 pharma companiesestimated an average of $2.23 billion per approved drug [https://www.fiercebiotech.com/biotech/drug-development-cost-pharma-22b-asset-2024-plus-how-glp-1s-impact-roi-deloitte]). The process is characterized by high attrition rates – only a small fraction of candidatecompounds eventually become approved medicines. For every 5,000–10,000 compounds initially screened, roughly 250 enter preclinicaltesting, about 5–10 progress to human trials, and ultimatelyonly 1is approved for use [https://en.wikipedia.org/wiki/Drug_development].These statistics underscore the tremendous risk and investment inherent in drug R&D. Pipeline Stages:The drug development pipeline consists ofdistinct phases. It begins withDrug Discovery, where researchers identifypromising targets and lead compounds through insights into disease biology, high-throughput screening, and medicinal chemistry.Promising leads undergoPreclinical Researchin labs and animal models to evaluate safety (toxicology), efficacy, and pharmacokinetics.If preclinical results are favorable, a formalInvestigational New Drug (IND) applicationis filed to regulatory authorities (like the U.S.FDA) to gain approval to startClinical Trialsin humans. Clinical development proceeds inPhase I(small-scale safety studies in healthyvolunteers or patients),Phase II(medium-scale trials in patients to assess efficacy and dosing), andPhase III(large-scale pivotal trials todefinitively establish safety and efficacy). Each successive phase involves more participants and more rigorous demonstration of thedrug’s therapeutic value. If Phase III results are successful, developers submit aNew Drug Application (NDA)orBiologics LicenseApplication (BLA)to regulators summarizing all findings. Regulatory agencies then conduct a thoroughReview and Approvalprocess,evaluating whether the drug’s benefits outweigh its risks. Upon approval, the drug enters the market, but the process continues withPhase IV Post-Marketing Surveillanceto monitor long-term safety in the general population and to fulfill any post-approval studycommitments [https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process]. Every step is governedby strict scientific and ethical standards to ensure patient safety and drug efficacy. Challenges and Attrition:The report highlights the major challenges contributing to the high failure rates in drug development.Approximately90% of drug candidates that enter clinical trials ultimately failto reach the market[https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/]. The leading causes of failure include lack of efficacy (responsible for ~40–50% offailures), unforeseen human toxicity or side effects (~30%), inadequate drug-like properties (e.g. poor pharmacokinetics) (~10–15%), andcommercial or strategic factors (~10%) [https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/]. These issues often manifest in Phase II orIII, where drugs sometimes proveineffectivein patients despite promising early data, or reveal safety problems when tested in largerpopulations. The report discusses how careful target selection, better predictive preclinical models, and adaptive trial designs are beingused to mitigate these risks. Regulatory and Historical Context:Modern drug development practices are deeply shaped by historical events andevolvingregulations. Notably, tragedies like the1937 sulfanilamide elixir poisoning (which killed 100+ people)prompted the 1938 FederalFood, Drug, and Cosmetic Act requiring proof of drug safety before marketing[https://www.theatlantic.com/technology/archive/2018/01/the-accidental-poison-that-founded-the-modern-fda/550574/]. Similarly, thethalidomide birth defects crisis of 1961–1962led to the Kefauver-Harris Amendments of 1962, which mandated rigorousdemonstration of drug efficacy and safety through controlled clinical trials prior to approval[https://www.theatlantic.com/technology/archive/2018/01/the-accidental-poison-that-founded-the-modern-fda/550574/]. These regulationsestablished theframework of phased clinical trials and the requirement of regulatory review, fundamentally shaping today’spipeline. Over time, additional regulatory pathways have been introduced to balancespeed and safety– for example,AcceleratedApprovala